UCB Announces First Detailed Data from Two Phase 3 Bimekizum

First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were...

Related Keywords

Brussels , Bruxelles Capitale , Belgium , Smyrna , Izmir , Turkey , Eimear Obrien , Antje Witte , J Clin Pharmacol , Brand Communications , Twitter , Corporate Communications , Ucb Inc , Drug Administration , American College Of Rheumatology , Source Ucb Inc , American College , Skin Symptoms , Psoriasis Area , Severity Index , Minimal Disease Activity , Total Sharp Score , Euronext Brussels , Psoriatic Arthritis , Week Efficacy , Active Reference , Active Psoriatic Arthritis , Inadequate Response , Tumour Necrosis Factor Inhibitors , Randomised Placebo Controlled , Rheum Dis Clin North , Subjects With Active Ankylosing Spondylitis , Ucb , Nc ,